| 标题 |
OptIMMize-1: a Randomized, Active-controlled, Efficacy Assessor-blinded Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Risankizumab in Patients From 6 to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis OptIMMize-1:一项随机、活性对照、疗效评估者设盲研究,旨在评估Risankizumab在6至18岁以下中度至重度斑块型银屑病患者中的药代动力学、安全性和疗效
|
| 网址 | |
| DOI |
暂未提供,该求助的时间将会延长,查看原因?
|
| 其它 | 2021,https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2019-004141-32-DE |
| 求助人 | |
| 下载 | 暂无链接,等待应助者上传 |